Saturday, 31 October 2026European Markets

CROSSWOOD Stock Over 28% Up In The Last 21 Sessions

Loading stream...

contrasting with an overall downward trend in the cac 40 - down by 0.69% - shares of paris-based real estate company crosswood (cac 40: cros.pa) have defied this trend. this company rose an incredible 28.144% over 21 sessions, seeing its share price rise to eur10.70 from eur8.00 today. this is an impressive recovery after five consecutive days of losses but still falls well short of its 52-week high of eur17.50.

crosswood's price-to-earnings ratio

crosswood's significant rise can be understood through its trailing twelve months (ttm) price-to-earnings ratio. at 18.77, this ratio indicates investors are currently paying eur18.77 per eur1 of earnings. this suggests a high level of optimism regarding the company's future earnings prospects among investors.

crosswood's current share valuation

another important factor to consider is the company's current share valuation. notably, this has exhibited significant progress above its average 50-day (eur8.98) and 200-day (eur8.83) moving averages, which may be read as an indication of a bullish trend. however, investors should bear in mind that while the price has surged above its 52-week low of eur6.65, it still sits considerably under its 52-week high of eur17.50.

estimated earnings and dividend yield

due to crosswood's estimated earnings per share (eps) of eur0.57 and its forward annual dividend yield of 1.5%, prospective investors should carefully weigh the potential returns against the share price, as well as the current volatile market conditions.

final words on crosswood

this analysis provides an overview of several key financial metrics related to crosswood. however, as with any investment, it is crucial to carry out comprehensive research before making definitive decisions relating to this stock.

more news about crosswood (cros.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com